Catalent Director of Research and Development to Present at Management Forum Conference on Dry Powder Inhalers
Research Triangle Park, NC, June 28, 2010 – Dr. Craig J. Davies-Cutting, Director, Research and Development at Catalent Pharma Solutions, will deliver a presentation titled, “Considerations and Approaches for Filling Dry Powder Inhalers (DPIs)” at the Management Forum Conference on Dry Powder Inhalers in London, UK. The presentation will be held on July 1 at 11:50 am. This international conference is one of the premier DPI and respiratory events of the year.
Dr. Davies-Cutting’s presentation gives consideration to Quality by Design (QbD) elements in the development and filling of "fit for purpose" Dry Powder Inhaler (DPI) products. Specific reference is provided to process scale up considerations in addition to the contribution of the powder formulation and DPI device. The presentation also compares and contrasts various DPI filling methodologies.
Dr. Davies-Cutting is located at Catalent’s facility in Research Triangle Park, NC where he is responsible for Pulmonary & Nasal Product Development activities along with Sterile Product Development and Analytical Research & Development. He has 23 years pharmaceutical industry experience of which 18 years have been in the inhalation arena. His educational background includes a B.Sc. in Applied Chemistry, Nottingham Trent University, UK; M.Sc. in Analytical Chemistry, University of London, UK and a Ph.D. in Colloids and Interface Science awarded by the University of Bristol, UK. He has served as an invited industrial representative on the Steering Committee for the Bristol Colloids Centre, an academic research consortium, affiliated to the University of Bristol, was the 2008 Chair for the North Carolina Pharmaceutical Discussion Group and currently sits as an editorial advisory board member for Inhalation magazine.
For more information on Catalent’s drug delivery systems and expertise in inhaled delivery, go to www.catalent.com/offerings/drug-delivery .
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion in annual revenue. For more information, visit www.catalent.com .